A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes

This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years

Study Overview

• Status: Completed
• Conditions: Obesity; Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: Placebo; Drug: Semaglutide; Drug: Semaglutide

• Study Type: Interventional
• Enrollment (Actual): 512
• Phase: Phase 3

Contacts and Locations

Study Locations

• Bulgaria
  • Blagoevgrad, Bulgaria, 2700
    • MHAT - Blagoevgrad AD, Department of Internal Diseases
  • Burgas, Bulgaria, 8000
    • IPSOMC - Dr. Georgi Marinov
  • Dobrich, Bulgaria, 9300
    • Medical Center Viva Feniks OOD
  • Pazardzhik, Bulgaria, 4400
    • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases
  • Plovdiv, Bulgaria, 4004
    • MHAT Sveta Karidad EAD
  • Sliven, Bulgaria, 8800
    • MHAT Hadzhi Dimitar OOD
  • Sofia, Bulgaria, 1233
    • DCC VII - Sofia EOOD, Endocrinology
  • Stara Zagora, Bulgaria, 6003
    • UMHAT Prof. Dr. Stoyan Kirkovich AD
  • Yambol, Bulgaria, 8600
    • MHAT Sveti Panteleimon - Yambol AD
• Canada
  • British Columbia
    • Surrey, British Columbia, Canada, V3Z 2N6
      • Ocean West Research Clinic
  • New Brunswick
    • Moncton, New Brunswick, Canada, E1G 1A7
      • G.A. Research Associates Ltd.
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 1V7
      • Nova Scotia Hlth Halifax
  • Ontario
    • Hamilton, Ontario, Canada, L8L 5G4
      • Premier Clinical Trial Research Network (PCTRN)
    • Hamilton, Ontario, Canada, L8L 5G8
      • Wharton Medical Clinic Clinical Trials (Hamilton)
    • London, Ontario, Canada, N5W 6A2
      • Milestone Research
• Hungary
  • Budapest, Hungary, 1106
    • Bajcsy-Zsilinszky Kórház
  • Budapest, Hungary, 1089
    • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
  • Budapest, Hungary, 1132
    • MED-TIMA Kft.
  • Székesfehérvár, Hungary, 8000
    • Fejér Megyei Szent György Oktatókórház
  • Bács-Kiskun county
    • Baja, Bács-Kiskun county, Hungary, 6500
      • Lausmed Kft.
  • Hajdú-Bihar
    • Debrecen, Hajdú-Bihar, Hungary, 4025
      • Belinus Bt.
  • Szabolcs-Szatmar Varmegye
    • Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary, 4405
      • Borbánya Praxis E.Ü. Kft.
• Poland
  • Katowice, Poland, 40-752
    • Uniwersyteckie Centrum Kliniczne SUM w Katowicach
  • Warsaw, Poland, 00-710
    • NBR Polska Tomasz Klodawski
  • Warsaw, Poland, 02-507
    • PANSTWOWY INSTYTUT MEDYCZNY MSWiA
  • Lesser Poland Voivodeship
    • Krakow, Lesser Poland Voivodeship, Poland, 31-261
      • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
  • Lubelski
    • Lublin, Lubelski, Poland, 20-538
      • NZOZ Przychodnia Specjalistyczna Medica
  • Lublin Voivodeship
    • Lublin, Lublin Voivodeship, Poland, 20-044
      • NZOZ "CenterMed Lublin" Sp. z o.o.
  • Podlaskie Voivodeship
    • Bialystok, Podlaskie Voivodeship, Poland, 15-481
      • Kresmed Sp. z o. o.
  • Pomeranian Voivodeship
    • Gdynia, Pomeranian Voivodeship, Poland, 81-338
      • Centrum Medyczne Pratia Gdynia
• Portugal
  • Lisbon, Portugal, 1250-230
    • APDP - Associação Protectora dos Diabéticos de Portugal
  • Lisbon, Portugal, 1349-019
    • Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz
  • Lisbon, Portugal, 1500-650
    • Hospital da Luz Lisboa, S.A.
  • Porto, Portugal, 4200-319
    • ULS De São João, E.P.E. - Hospital de São João
  • Vila Nova de Gaia, Portugal, 4400-346
    • Hospital da Luz Arrabida, S.A.
  • Matosinhos
    • Senhora Da Hora, Matosinhos, Matosinhos, Portugal, 4464-513
      • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
• Slovakia
  • Bardejov, Slovakia, 08501
    • DIADA s.r.o.
  • Bardejov, Slovakia, 08501
    • DIADA, s.r.o.
  • Bytča, Slovakia, 014 01
    • Diab - Int, s.r.o.
  • Košice, Slovakia, 04013
    • Endomed, s.r.o.
  • Považská Bystrica, Slovakia, 01701
    • MED-DIA CENTRUM s.r.o.
  • Prešov, Slovakia, 080 01
    • DIABETOL, s.r.o.
• South Africa
  • Eastern Cape
    • Port Elizabeth, Eastern Cape, South Africa, 6001
      • Phoenix Pharma
  • Free State
    • Bloemfontein, Free State, South Africa, 9301
      • Medi-Clinic Bloemfontein
  • Gauteng
    • Johannesburg, Gauteng, South Africa, 1820
      • Deepak Lakha
    • Johannesburg, Gauteng, South Africa, 1827
      • Hemant Makan
    • Johannesburg, Gauteng, South Africa, 2013
      • Wits Bara Clinical Trial Site
    • Johannesburg, Gauteng, South Africa, 1818
      • Soweto Clinical Trial Centre
  • KwaZulu-Natal
    • Durban, KwaZulu-Natal, South Africa, 4001
      • Maxwell Centre
    • Durban, KwaZulu-Natal, South Africa, 4092
      • Precise Clinical Solutions (Pty) Ltd
    • Durban, KwaZulu-Natal, South Africa, 4901
      • Lenmed Shifa Private Hospital
    • Durban, KwaZulu-Natal, South Africa, 4093
      • Dr N.K. Gounden Medical Centre
    • eMkhomazi, KwaZulu-Natal, South Africa, 4170
      • Dr T Padayachee
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35222
      • Univ of Alabama Birmingham
    • Montgomery, Alabama, United States, 36106
      • Chambliss Clinical Trials, LLC
  • California
    • Concord, California, United States, 94520
      • John Muir Physicians Network
    • Los Angeles, California, United States, 90057
      • Velocity Clinical Research Westlake
    • Walnut Creek, California, United States, 94598
      • Diablo Clinical Research, Inc.
  • Colorado
    • Golden, Colorado, United States, 80401
      • New West Physicians PC
  • Florida
    • DeLand, Florida, United States, 32720
      • ARS- Deland CRU
    • Jacksonville, Florida, United States, 32216
      • Jacksonville Ctr For Clin Res
    • Orlando, Florida, United States, 32825
      • Florida Inst For Clin Res LLC
    • Oviedo, Florida, United States, 32765
      • Oviedo Medical Research, LLC
  • Georgia
    • Conyers, Georgia, United States, 30094
      • Hope Clin Res & Wellness
  • New York
    • Albany, New York, United States, 12203
      • AMC Community Endocrinology
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27514
      • University of North Carolina
    • Greensboro, North Carolina, United States, 27408
      • PharmQuest Life Sciences LLC
  • Texas
    • Amarillo, Texas, United States, 79106
      • Amarillo Med Spec LLP
    • Austin, Texas, United States, 78704
      • Elligo Clin Res Centre
    • Dallas, Texas, United States, 75230
      • Velocity Clin Res, Dallas
    • Dallas, Texas, United States, 75390
      • UT Southwestern Medical Center - Lingvay
    • Houston, Texas, United States, 77079
      • PlanIt Research, PLLC
    • Longview, Texas, United States, 75605
      • DCOL Ctr for Clin Res
    • Sugar Land, Texas, United States, 77479
      • Sugar Lakes Family Practice PA
  • Virginia
    • Richmond, Virginia, United States, 23294
      • National Clin Res Inc.
    • Winchester, Virginia, United States, 22601-3834
      • Selma Medical Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Male or female.
• Age above or equal to 18 years at the time of signing informed consent.
• BMI greater than or equal to 30.0 kilograms per square meter (kg/m^2).
• Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening.
• History of at least one self-reported unsuccessful dietary effort to lose body weight.
• HbA1c 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening.

Exclusion Criteria:

• A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds [lbs]) within 90 days before screening irrespective of medical records.
• Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
• Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m^2) (less than 45 mL/min/1.73 m^2 in participants treated with Sodium-glucose Cotransporter-2 [SGLT2i]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening.
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.	Drug: Placebo; Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Experimental: Semaglutide 7.2 mg; Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram [mg], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.	Drug: Semaglutide; Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.; Drug: Semaglutide; Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Experimental: Semaglutide 2.4 mg; Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.	Drug: Semaglutide; Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.; Drug: Semaglutide; Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relative Change in Body Weight	Relative change in body weight from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)	Number of participants who achieve body weight reduction >=5% is presented. Yes defines participants who achieved body weight reduction >= 5% and No defines participants who did not achieve body weight reduction >=5%.	At week 72

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Achieve Body Weight Reduction >= 10% (Yes/no)	Number of participants who achieve body weight reduction >=10% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 10% and No defines participants who did not achieve body weight reduction greater than or equal to 10%.	At week 72
Number of Participants Who Achieve Body Weight Reduction >= 15% (Yes/no)	Number of participants who achieve body weight reduction >=15% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 15% and No defines participants who did not achieve body weight reduction greater than or equal to 15%.	At week 72
Number of Participants Who Achieve Body Weight Reduction >= 20% (Yes/no)	Number of participants who achieve body weight reduction >=20% is presented. Yes defines participants who achieved body weight reduction greater than or equal to 20% and No defines participants who did not achieve body weight reduction greater than or equal to 20%.	At week 72
Change in Waist Circumference	Change in waist circumference from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Glycated Haemoglobin (HbA1c)	Change in HbA1c from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Body Weight	Change in body weight from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Body Mass Index (BMI)	Change in BMI from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Systolic Blood Pressure	Change in systolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Diastolic Blood Pressure	Change in diastolic blood pressure from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Total Cholesterol (Millimoles Per Liter [mmol/L]) - Ratio to Baseline	Change in total cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Total Cholesterol (Milligrams Per Deciliter [mg/dL]) - Ratio to Baseline	Change in total cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in High-density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline	Change in HDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in HDL Cholesterol (mg/dL) - Ratio to Baseline	Change in HDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Low-density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline	Change in LDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in LDL Cholesterol (mg/dL) - Ratio to Baseline	Change in LDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Very-low-density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline	Change in VLDL cholesterol in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in VLDL Cholesterol (mg/dL) - Ratio to Baseline	Change in VLDL cholesterol in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Triglycerides (mmol/L) - Ratio to Baseline	Change in triglycerides in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Triglycerides (mg/dL) - Ratio to Baseline	Change in triglycerides in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Free Fatty Acids (mmol/L) - Ratio to Baseline	Change in free fatty acids in mmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Free Fatty Acids (mg/dL) - Ratio to Baseline	Change in free fatty acids in mg/dL from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in High-sensitivity C-reactive Protein (hsCRP) - Ratio to Baseline	Change in hsCRP in mg/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Fasting Plasma Glucose	Change in fasting plasma glucose from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Change in Fasting Serum Insulin (Picomoles Per Liter [Pmol/L]) - Ratio to Baseline	Change in fasting serum insulin in pmol/L from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Change in Fasting Serum Insulin (Milliinternational Units Per Milliliter [mIU/mL]) - Ratio to Baseline	Change in fasting serum insulin in mIU/ml from baseline (week 0) to end of treatment (week 72) as ratio to baseline is presented.	Baseline (week 0), End of treatment (week 72)
Number of Participants With HbA1c Less Than 7.0 % (53 Millimoles Per Mole [mmol/Mol])	Number of participants with HbA1c less than 7.0 % (53 mmol/mol) at week 72 is presented.	At week 72
Number of Participants With HbA1c Less Than or Equal to 6.5% (48 mmol/Mol)	Number of participants with HbA1c less than or equal to 6.5% (48 mmol/mol) at week 72 is presented.	At week 72
Semaglutide 7.2 mg Versus Placebo: Number of Adverse Events (AEs)	Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.	At week 81
Semaglutide 7.2 mg Versus Placebo: Number of Serious Adverse Events (SAEs)	Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.	At week 81
Change in Pulse	Change in pulse from baseline (week 0) to end of treatment (week 72) is presented.	Baseline (week 0), End of treatment (week 72)
Semaglutide 7.2 mg Versus Placebo: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes	Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.	At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of AEs	Number of AEs is reported. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP.	At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of SAEs	Number of SAEs is reported. A SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical event.	At week 81
Semaglutide 7.2 mg Versus Semaglutide 2.4 mg: Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes	Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes is presented.	At week 81

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S
• Investigators: Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Publications and helpful links

General Publications

• Lingvay I, Bergenheim SJ, Buse JB, Freitas P, Garvey WT, Harder-Lauridsen NM, Rosenstock J, Sahu K, Wharton S; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025 Nov;13(11):935-948. doi: 10.1016/S2213-8587(25)00225-6. Epub 2025 Sep 14.

Study record dates

Study Major Dates

• Study Start (Actual): January 4, 2023
• Primary Completion (Actual): October 28, 2024
• Study Completion (Actual): December 13, 2024

Study Registration Dates

• First Submitted: December 5, 2022
• First Submitted That Met QC Criteria: December 5, 2022
• First Posted (Actual): December 13, 2022

Study Record Updates

• Last Update Posted (Actual): April 27, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Diabetes Mellitus; Overweight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor Agonists; Physiological Effects of Drugs; Hypoglycemic Agents; semaglutide
• Other Study ID Numbers: NN9536-7545; 2022-002235-60 (EudraCT Number); U1111-1279-0359 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No